Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.
Metagenomi Therapeutics, Inc. is an emerging growth company focused on genome editing technology, reporting 37,805,669 shares of common stock outstanding as of November 6, 2026. The filing highlights ongoing research and development programs, preclinical proof-of-concept goals, and risks related to macroeconomic volatility and regulatory developments.
Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.
“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”
Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
Metagenomi Therapeutics, Inc. filed a corporate presentation dated September 2026 as an exhibit to its 8-K. The presentation outlines the company's strategy for precision gene editing and the development of curative medicines. The filing is a standard Regulation FD disclosure used to provide updated information to investors and analysts.